StockStorm.ai

Immunic, Inc.

IMUX Stock News

Latest IMUX news

Immunic to host virtual relapsing MS R&D Day on September 9

Proactive Investors · Wed, 02 Sep 2026 08:54:44 -0400

Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it will host a virtual research and development day focused on relapsing multiple sclerosis on September 9, as the biotechnology company prepares for topline results from its Phase 3 ENSURE trials expected by the end of 2026. The event will feature Immunic management, including CEO Erik Lundgren, chief medical officer Michael Panzara, chief scientific officer Hella Kohlhof and president and chief operating officer Jason Tardio.

Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026

PRNewsWire · Wed, 02 Sep 2026 06:30:00 -0400

NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual research and development (R&D) day focused on relapsing multiple sclerosis (MS) on Wednesday, September 9, 2026, at 11:00 am ET.

Immunic Appoints Chitrang Davé as Chief Data and Digital Officer

PRNewsWire · Tue, 01 Sep 2026 06:30:00 -0400

– New C-Suite Role and Appointment Underscore Commitment to Building a Strong, Commercial-Ready Data Ecosystem, in Preparation for Potential NDA Submission and Commercialization – NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Chitrang Davé as Chief Data and Digital Officer (CDDO), effective today.

Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating

Seeking Alpha · Tue, 25 Aug 2026 10:50:35 -0400

Immunic is advancing vidofludimus calcium (IMU-838) in late-stage trials for both relapsing and progressive multiple sclerosis. MS represents a substantial market, with existing therapies projected to reach ~$22 billion in 2026 revenues. IMU-838's oral administration and differentiated mechanism of action position it as a potential major player in the MS market.

Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?

Zacks Investment Research · Thu, 13 Aug 2026 10:56:10 -0400

The mean of analysts' price targets for Immunic (IMUX) points to a 163% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Proactive Investors · Tue, 11 Aug 2026 08:40:23 -0400

Immunic Inc (NASDAQ:IMUX, FRA:10VA) is preparing for a series of clinical and corporate milestones as it advances its lead drug candidate vidofludimus calcium through late-stage development in multiple sclerosis, while expanding its leadership team ahead of potential regulatory filings and commercialization. The biotechnology company reported second-quarter results on Tuesday and said its Phase 3 ENSURE-1 and ENSURE-2 trials evaluating vidofludimus calcium in relapsing multiple sclerosis remain on track to deliver top-line data by the end of 2026.

Market information is provided for research and visualization and is not investment advice.